Please enable JavaScript to continue using this application.

Compare $CHRS vs $TARA | Chartloom

Compare

$CHRS vs $TARA

Coherus Oncology Inc · Protara Therapeutics Inc

CHRS

Coherus Oncology Inc

TARA

Protara Therapeutics Inc

Compare $CHRS vs $TARA

Comparing Coherus Oncology Inc and Protara Therapeutics Inc

CHRSCoherus Oncology Inc

TARAProtara Therapeutics Inc

CHRSCoherus Oncology Inc

Market cap

$165M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.04x

Rev growth (TTM)

-64.3%

YTD performance

-21.9%

52W performance

-39.2%

FCF yield

-112.7%

TARAProtara Therapeutics Inc

Market cap

$155M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-48.8%

52W performance

-45.7%

FCF yield

-42.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CHRS

TARA

Detailed metrics comparison

CHRS

Coherus Oncology Inc

TARA

Protara Therapeutics Inc

Market Cap

CHRS$165M

TARA$155M

Enterprise Value

CHRS$134M

TARA$138M

Price

CHRS$1.07

TARA$2.76

P/E Ratio

CHRSN/A

TARAN/A

P/S Ratio

CHRS3.24x

TARA0.00x

EV/Sales

CHRS2.63x

TARA0.00x

EV/EBITDA

CHRS2.57x

TARA0.00x

P/B Ratio

CHRS2.95x

TARA0.99x

P/FCF Ratio

CHRSN/A

TARAN/A

EV/FCF

CHRS-0.72x

TARA-2.07x

PEG Ratio

CHRSN/A

TARAN/A

Forward P/E (NTM)

CHRSN/A

TARAN/A

Forward P/S (NTM)

CHRS2.04x

TARAN/A

Revenue (TTM)

CHRS$51M

TARA$0

Revenue Growth (YoY)

CHRS-64.3%

TARAN/A

Forward Rev Growth

CHRS67.8%

TARA5488.8%

Gross Margin (TTM)

CHRS68.9%

TARA0.0%

Operating Margin (TTM)

CHRS0.0%

TARA0.0%

EBITDA Margin (TTM)

CHRS-288.0%

TARA0.0%

Net Margin (TTM)

CHRS-259.4%

TARA0.0%

FCF Margin (TTM)

CHRS-365.2%

TARAN/A

Net Income (TTM)

CHRS$-132M

TARA$-70M

FCF (TTM)

CHRS$-186M

TARA$-66M

EPS (TTM)

CHRS-$0.85

TARA-$1.15

ROE (TTM)

CHRS-18336.0%

TARA-4172.0%

ROA (TTM)

CHRS-4290.0%

TARA-3878.0%

ROIC (TTM)

CHRS-10716.0%

TARA-4172.0%

Cash

CHRS$83M

TARA$17M

Debt

CHRS$52M

TARA$0

Net Cash/Debt

CHRS$31M

TARA$17M

Current Ratio (TTM)

CHRS1.77x

TARA10.97x

Quick Ratio (TTM)

CHRS1.58x

TARA10.81x

Debt/Equity (TTM)

CHRS0.85x

TARA0.00x

Debt/Assets (TTM)

CHRS0.0%

TARA0.0%

Interest Coverage (TTM)

CHRSN/A

TARAN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

TARA0.00x

Beta

CHRS0.99

TARA1.54

52W Performance

CHRS-39.2%

TARA-45.7%

YTD Performance

CHRS-21.9%

TARA-48.8%

% from 52W High

CHRS-59.1%

TARA-64.8%

% from 52W Low

CHRS9.9%

TARA9.8%

Asset Turnover (TTM)

CHRS0.17x

TARA0.00x

FCF Yield (TTM)

CHRS-112.7%

TARA-42.9%

Earnings Yield (TTM)

CHRS-80.1%

TARA-45.2%

Dividend Yield (TTM)

CHRSN/A

TARAN/A

Rule of 40

CHRS-429.5

TARA0.0

EV/GP/RG

CHRS0.05

TARAN/A

Ticker research

View CHRS research View TARA research

Metric	CHRS Coherus Oncology Inc	TARA Protara Therapeutics Inc
Market & Valuation
Market Cap	$165M	$155M
Enterprise Value	$134M	$138M
Price	$1.07	$2.76
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	0.00x
EV/Sales	2.63x	0.00x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.99x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-2.07x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	N/A
Revenue & Growth
Revenue (TTM)	$51M	$0
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	5488.8%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	0.0%
Net Margin (TTM)	-259.4%	0.0%
FCF Margin (TTM)	-365.2%	N/A
Net Income (TTM)	$-132M	$-70M
FCF (TTM)	$-186M	$-66M
EPS (TTM)	-$0.85	-$1.15
ROE (TTM)	-18336.0%	-4172.0%
ROA (TTM)	-4290.0%	-3878.0%
ROIC (TTM)	-10716.0%	-4172.0%
Financial Health
Cash	$83M	$17M
Debt	$52M	$0
Net Cash/Debt	$31M	$17M
Current Ratio (TTM)	1.77x	10.97x
Quick Ratio (TTM)	1.58x	10.81x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.54
52W Performance	-39.2%	-45.7%
YTD Performance	-21.9%	-48.8%
% from 52W High	-59.1%	-64.8%
% from 52W Low	9.9%	9.8%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	-112.7%	-42.9%
Earnings Yield (TTM)	-80.1%	-45.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	0.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View TARA research

Valuation

P/S Ratio

TARA

0.00x

CHRS

3.24x

EV/FCF

TARA

-2.07x

CHRS

-0.72x

Growth & revenue

Revenue Growth TTM

CHRS

-64.3%

Forward Revenue Growth

TARA

5488.8%

CHRS

67.8%

Profitability & performance

Gross Margin

CHRS

68.9%

TARA

0.0%

ROE

TARA

-4172.0%

CHRS

-18336.0%

FCF Yield %

TARA

-42.9%

CHRS

-112.7%

52-Week Performance

CHRS

-39.2%

TARA

-45.7%

Detailed metrics comparison

CHRS

Coherus Oncology Inc

TARA

Protara Therapeutics Inc

Market Cap

CHRS$165M

TARA$155M

Enterprise Value

CHRS$134M

TARA$138M

Price

CHRS$1.07

TARA$2.76

P/E Ratio

CHRSN/A

TARAN/A

P/S Ratio

CHRS3.24x

TARA0.00x

EV/Sales

CHRS2.63x

TARA0.00x

EV/EBITDA

CHRS2.57x

TARA0.00x

P/B Ratio

CHRS2.95x

TARA0.99x

P/FCF Ratio

CHRSN/A

TARAN/A

EV/FCF

CHRS-0.72x

TARA-2.07x

PEG Ratio

CHRSN/A

TARAN/A

Forward P/E (NTM)

CHRSN/A

TARAN/A

Forward P/S (NTM)

CHRS2.04x

TARAN/A

Revenue (TTM)

CHRS$51M

TARA$0

Revenue Growth (YoY)

CHRS-64.3%

TARAN/A

Forward Rev Growth

CHRS67.8%

TARA5488.8%

Gross Margin (TTM)

CHRS68.9%

TARA0.0%

Operating Margin (TTM)

CHRS0.0%

TARA0.0%

EBITDA Margin (TTM)

CHRS-288.0%

TARA0.0%

Net Margin (TTM)

CHRS-259.4%

TARA0.0%

FCF Margin (TTM)

CHRS-365.2%

TARAN/A

Net Income (TTM)

CHRS$-132M

TARA$-70M

FCF (TTM)

CHRS$-186M

TARA$-66M

EPS (TTM)

CHRS-$0.85

TARA-$1.15

ROE (TTM)

CHRS-18336.0%

TARA-4172.0%

ROA (TTM)

CHRS-4290.0%

TARA-3878.0%

ROIC (TTM)

CHRS-10716.0%

TARA-4172.0%

Cash

CHRS$83M

TARA$17M

Debt

CHRS$52M

TARA$0

Net Cash/Debt

CHRS$31M

TARA$17M

Current Ratio (TTM)

CHRS1.77x

TARA10.97x

Quick Ratio (TTM)

CHRS1.58x

TARA10.81x

Debt/Equity (TTM)

CHRS0.85x

TARA0.00x

Debt/Assets (TTM)

CHRS0.0%

TARA0.0%

Interest Coverage (TTM)

CHRSN/A

TARAN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

TARA0.00x

Beta

CHRS0.99

TARA1.54

52W Performance

CHRS-39.2%

TARA-45.7%

YTD Performance

CHRS-21.9%

TARA-48.8%

% from 52W High

CHRS-59.1%

TARA-64.8%

% from 52W Low

CHRS9.9%

TARA9.8%

Asset Turnover (TTM)

CHRS0.17x

TARA0.00x

FCF Yield (TTM)

CHRS-112.7%

TARA-42.9%

Earnings Yield (TTM)

CHRS-80.1%

TARA-45.2%

Dividend Yield (TTM)

CHRSN/A

TARAN/A

Rule of 40

CHRS-429.5

TARA0.0

EV/GP/RG

CHRS0.05

TARAN/A

Ticker research

View CHRS research View TARA research

Metric	CHRS Coherus Oncology Inc	TARA Protara Therapeutics Inc
Market & Valuation
Market Cap	$165M	$155M
Enterprise Value	$134M	$138M
Price	$1.07	$2.76
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	0.00x
EV/Sales	2.63x	0.00x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.99x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-2.07x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	N/A
Revenue & Growth
Revenue (TTM)	$51M	$0
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	5488.8%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	0.0%
Net Margin (TTM)	-259.4%	0.0%
FCF Margin (TTM)	-365.2%	N/A
Net Income (TTM)	$-132M	$-70M
FCF (TTM)	$-186M	$-66M
EPS (TTM)	-$0.85	-$1.15
ROE (TTM)	-18336.0%	-4172.0%
ROA (TTM)	-4290.0%	-3878.0%
ROIC (TTM)	-10716.0%	-4172.0%
Financial Health
Cash	$83M	$17M
Debt	$52M	$0
Net Cash/Debt	$31M	$17M
Current Ratio (TTM)	1.77x	10.97x
Quick Ratio (TTM)	1.58x	10.81x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.54
52W Performance	-39.2%	-45.7%
YTD Performance	-21.9%	-48.8%
% from 52W High	-59.1%	-64.8%
% from 52W Low	9.9%	9.8%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	-112.7%	-42.9%
Earnings Yield (TTM)	-80.1%	-45.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	0.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View TARA research